Unknown Lungs & Breathing NIHR-supported project Digestion, Kidneys & Other Organs

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled Study to Evaluate Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to <18 Years of Age with Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy

Funder NIHR (part of DHSC)
Recipient organisation NIHR Wellcome Trust Manchester Clinical Research Facility
NIHR support Recorded as supported by this research centre
Period Mar 2025 — Ongoing

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Hanna Lythgoe (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A Phase III, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of IV Anifrolumab in pediatric participants 5 to < 18 years of age with moderate to severe active systemic lupus erythematosus while on background standard of care therapy.
Phase III, Randomised, double-blind, parallel-group, placebo-controlled study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of IV Anifrolumab in paediatric participants 5 to < 18 years of age with moderate to severe active Systemic Lupus Erythematosus (SLE).While on background standard of care therapy
A Phase III, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of IV Anifrolumab in pediatric participants 5 to < 18 years of age with moderate to severe active systemic lupus erythematosus while on background standard of care therapy. (BLOSSOM)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy
Lavender - A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.